Schizophrenia therapy - Eli Lilly and Company
Latest Information Update: 29 Apr 2013
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 17 Apr 2013 Discontinued - Phase-I for Schizophrenia in USA (unspecified route)
- 15 Apr 2009 Phase-I clinical trials in Schizophrenia in USA (unspecified route)